Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DB5UO0
|
|||
| Drug Name |
CAN04
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162] | Phase 1 | [1] | |
| Company |
Cantargia
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin 1 receptor accessory protein (IL1RAP) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04452214) A Study of the Safety and Tolerance of CAN04 in Combination With Pembrolizumab in Subjects With Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors (CANFOUR) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.